Remix Therapeutics

Remix Therapeutics is a biotechnology research company dedicated to transforming patients' lives through the modulation of RNA processing. Remix Therapeutics is focused on addressing drug targets in diseases with high unmet medical needs.

With the help of the REMaster™ technology platform, Remix Therapeutics leverages data science, biomolecular sciences, and chemistry approaches to identify orally administered compounds that modulate gene expression. This innovative therapeutic approach has led to the discovery of REM-422, a first-in-class RNA processing modulator in oncology, currently in Phase 1 clinical studies for treating acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS), and adenoid cystic carcinoma (ACC).

Located at 100 Forge Rd, Watertown, MA, MA 02472, US, Remix Therapeutics is committed to developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. To explore opportunities for a customized and exclusive company showcase and product listing, we invite the manager of Remix Therapeutics to contact us.